John Libbey Eurotext

Journal de Pharmacie Clinique

Highlights of the 2017 ISPOR conference Volume 36, issue 3, Septembre 2017

Figures

  • Figure 1
  • Figure 2

Tables

Authors
1 Service de pharmacie-stérilisation, Hôpitaux universitaires de Strasbourg et Laboratoire HuManiS (EA 7308), Strasbourg, France
2 Pôle information médicale, évaluation, recherche, Unité d’évaluation médico-économique, Hospices civils de Lyon, Lyon, France ; Université Claude Bernard Lyon 1, Hesper EA 7425, Lyon, France
3 Service de pharmacie hospitalière, Hôpital d’instruction des armées Desgenettes, Lyon, France
4 Service pharmacie, Hôpital Antoine Béclère, GH HUPS, AP-HP, Clamart, France
5 Service pharmacie, CHU Charles Nicolle, Rouen, France
6 Pôle pharmacie, Grand Hôpital de l’Est Francilien, Meaux, France
* Tirés à part
  • Key words: big data, real life, health products, ISPOR, pharmacoeconomics
  • DOI : 10.1684/jpc.2017.0362
  • Page(s) : 153-67
  • Published in: 2017

The 22nd ISPOR (International society for pharmacoeconomics and outcomes research) Conference was held in Boston, May 20-24, 2017. A group of pharmacists, physicians and health economists attended the conference and reported some of the highlights. During the congress, there was a widespread and enthusiastic debate on the exploitation of big data, their usefulness for health policy decisions and coming challenges. In this paper, the authors discussed the following questions from the different sessions and/or posters: Real-life databases: What are they? What reliability and methodologies? What operating potentials? What uses are applied to medical devices? Will they be able to supplement the randomized clinical trials?